nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—malignant glioma	0.48	1	CbGaD
Erlotinib—CYP1A2—Carmustine—malignant glioma	0.0452	0.57	CbGbCtD
Erlotinib—CYP3A4—Temozolomide—malignant glioma	0.0341	0.431	CbGbCtD
Erlotinib—Lung infection—Temozolomide—malignant glioma	0.00856	0.065	CcSEcCtD
Erlotinib—Disease progression—Carmustine—malignant glioma	0.00666	0.0506	CcSEcCtD
Erlotinib—Pulmonary toxicity—Carmustine—malignant glioma	0.0064	0.0486	CcSEcCtD
Erlotinib—ORM1—vertebral column—malignant glioma	0.00427	0.0502	CbGeAlD
Erlotinib—Pulmonary fibrosis—Carmustine—malignant glioma	0.0033	0.0251	CcSEcCtD
Erlotinib—Pulmonary fibrosis—Temozolomide—malignant glioma	0.00319	0.0243	CcSEcCtD
Erlotinib—Lung infiltration—Carmustine—malignant glioma	0.0031	0.0235	CcSEcCtD
Erlotinib—Interstitial pneumonia—Temozolomide—malignant glioma	0.00291	0.0221	CcSEcCtD
Erlotinib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00263	0.0199	CcSEcCtD
Erlotinib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00254	0.0193	CcSEcCtD
Erlotinib—Skin hyperpigmentation—Carmustine—malignant glioma	0.00244	0.0186	CcSEcCtD
Erlotinib—Deep vein thrombosis—Temozolomide—malignant glioma	0.00231	0.0175	CcSEcCtD
Erlotinib—Interstitial lung disease—Carmustine—malignant glioma	0.00205	0.0156	CcSEcCtD
Erlotinib—Myopathy—Temozolomide—malignant glioma	0.002	0.0152	CcSEcCtD
Erlotinib—Interstitial lung disease—Temozolomide—malignant glioma	0.00198	0.0151	CcSEcCtD
Erlotinib—Lung disorder—Temozolomide—malignant glioma	0.00198	0.0151	CcSEcCtD
Erlotinib—Hepatotoxicity—Carmustine—malignant glioma	0.00188	0.0143	CcSEcCtD
Erlotinib—Hepatotoxicity—Temozolomide—malignant glioma	0.00182	0.0138	CcSEcCtD
Erlotinib—Vandetanib—KDR—malignant glioma	0.00177	0.308	CrCbGaD
Erlotinib—PIP4K2C—retina—malignant glioma	0.00172	0.0202	CbGeAlD
Erlotinib—Rigors—Temozolomide—malignant glioma	0.00172	0.0131	CcSEcCtD
Erlotinib—ULK3—retina—malignant glioma	0.00164	0.0193	CbGeAlD
Erlotinib—EGFR—telencephalon—malignant glioma	0.00163	0.0192	CbGeAlD
Erlotinib—PIP4K2C—telencephalon—malignant glioma	0.00158	0.0186	CbGeAlD
Erlotinib—Drug interaction—Carmustine—malignant glioma	0.00157	0.0119	CcSEcCtD
Erlotinib—MKNK1—retina—malignant glioma	0.00155	0.0182	CbGeAlD
Erlotinib—ULK3—telencephalon—malignant glioma	0.00151	0.0178	CbGeAlD
Erlotinib—Vandetanib—VEGFA—malignant glioma	0.0015	0.261	CrCbGaD
Erlotinib—MKNK1—telencephalon—malignant glioma	0.00142	0.0167	CbGeAlD
Erlotinib—Musculoskeletal pain—Temozolomide—malignant glioma	0.00142	0.0108	CcSEcCtD
Erlotinib—Skin exfoliation—Carmustine—malignant glioma	0.00139	0.0105	CcSEcCtD
Erlotinib—Neuropathy—Carmustine—malignant glioma	0.00136	0.0104	CcSEcCtD
Erlotinib—AURKC—central nervous system—malignant glioma	0.00136	0.016	CbGeAlD
Erlotinib—SLK—telencephalon—malignant glioma	0.00135	0.0158	CbGeAlD
Erlotinib—Skin exfoliation—Temozolomide—malignant glioma	0.00134	0.0102	CcSEcCtD
Erlotinib—Neuropathy—Temozolomide—malignant glioma	0.00132	0.01	CcSEcCtD
Erlotinib—Dry eye—Temozolomide—malignant glioma	0.0013	0.00985	CcSEcCtD
Erlotinib—HIPK4—brain—malignant glioma	0.00127	0.0149	CbGeAlD
Erlotinib—Vandetanib—EGFR—malignant glioma	0.00127	0.221	CrCbGaD
Erlotinib—JAK3—central nervous system—malignant glioma	0.00126	0.0149	CbGeAlD
Erlotinib—EPHA6—central nervous system—malignant glioma	0.00126	0.0149	CbGeAlD
Erlotinib—Sepsis—Carmustine—malignant glioma	0.00126	0.00958	CcSEcCtD
Erlotinib—LTK—brain—malignant glioma	0.00125	0.0147	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—malignant glioma	0.00124	0.0146	CbGeAlD
Erlotinib—JAK3—cerebellum—malignant glioma	0.00123	0.0145	CbGeAlD
Erlotinib—Gefitinib—EGFR—malignant glioma	0.0012	0.21	CrCbGaD
Erlotinib—ULK3—medulla oblongata—malignant glioma	0.00119	0.014	CbGeAlD
Erlotinib—MAP2K5—brainstem—malignant glioma	0.00118	0.0139	CbGeAlD
Erlotinib—MAP3K19—central nervous system—malignant glioma	0.00115	0.0135	CbGeAlD
Erlotinib—PIP4K2C—midbrain—malignant glioma	0.00114	0.0134	CbGeAlD
Erlotinib—Hepatic failure—Temozolomide—malignant glioma	0.00113	0.00862	CcSEcCtD
Erlotinib—TNK1—cerebellum—malignant glioma	0.00113	0.0133	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—malignant glioma	0.00112	0.0131	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—malignant glioma	0.00111	0.013	CbGeAlD
Erlotinib—ULK3—midbrain—malignant glioma	0.00109	0.0128	CbGeAlD
Erlotinib—AURKC—brain—malignant glioma	0.00108	0.0127	CbGeAlD
Erlotinib—ULK3—spinal cord—malignant glioma	0.00106	0.0125	CbGeAlD
Erlotinib—SLK—medulla oblongata—malignant glioma	0.00106	0.0124	CbGeAlD
Erlotinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00106	0.00801	CcSEcCtD
Erlotinib—MAP2K5—telencephalon—malignant glioma	0.00105	0.0123	CbGeAlD
Erlotinib—MKNK1—midbrain—malignant glioma	0.00102	0.012	CbGeAlD
Erlotinib—JAK3—brain—malignant glioma	0.001	0.0118	CbGeAlD
Erlotinib—EPHA6—brain—malignant glioma	0.001	0.0118	CbGeAlD
Erlotinib—MKNK1—spinal cord—malignant glioma	0.000997	0.0117	CbGeAlD
Erlotinib—ABL1—embryo—malignant glioma	0.000993	0.0117	CbGeAlD
Erlotinib—FLT3—cerebellum—malignant glioma	0.000974	0.0114	CbGeAlD
Erlotinib—SLK—midbrain—malignant glioma	0.000968	0.0114	CbGeAlD
Erlotinib—Hypokalaemia—Carmustine—malignant glioma	0.00096	0.00729	CcSEcCtD
Erlotinib—Dehydration—Temozolomide—malignant glioma	0.000948	0.0072	CcSEcCtD
Erlotinib—SLK—spinal cord—malignant glioma	0.000944	0.0111	CbGeAlD
Erlotinib—Dry skin—Temozolomide—malignant glioma	0.000935	0.0071	CcSEcCtD
Erlotinib—ABL2—cerebellum—malignant glioma	0.00093	0.0109	CbGeAlD
Erlotinib—Hypokalaemia—Temozolomide—malignant glioma	0.000928	0.00705	CcSEcCtD
Erlotinib—TNK1—brain—malignant glioma	0.000921	0.0108	CbGeAlD
Erlotinib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000918	0.00697	CcSEcCtD
Erlotinib—Dysphagia—Carmustine—malignant glioma	0.000912	0.00692	CcSEcCtD
Erlotinib—MAP3K19—brain—malignant glioma	0.000911	0.0107	CbGeAlD
Erlotinib—ABL1—brainstem—malignant glioma	0.00091	0.0107	CbGeAlD
Erlotinib—EGFR—cerebellum—malignant glioma	0.000907	0.0107	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—malignant glioma	0.0009	0.0106	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000899	0.00683	CcSEcCtD
Erlotinib—Dysphagia—Temozolomide—malignant glioma	0.000881	0.00669	CcSEcCtD
Erlotinib—PIP4K2C—cerebellum—malignant glioma	0.00088	0.0103	CbGeAlD
Erlotinib—ABL1—retina—malignant glioma	0.000878	0.0103	CbGeAlD
Erlotinib—ULK3—central nervous system—malignant glioma	0.000859	0.0101	CbGeAlD
Erlotinib—Neutropenia—Carmustine—malignant glioma	0.000853	0.00648	CcSEcCtD
Erlotinib—ULK3—cerebellum—malignant glioma	0.00084	0.00988	CbGeAlD
Erlotinib—Neutropenia—Temozolomide—malignant glioma	0.000824	0.00626	CcSEcCtD
Erlotinib—MAP2K5—medulla oblongata—malignant glioma	0.000822	0.00967	CbGeAlD
Erlotinib—Pneumonia—Carmustine—malignant glioma	0.000818	0.00621	CcSEcCtD
Erlotinib—SLCO2B1—telencephalon—malignant glioma	0.000814	0.00957	CbGeAlD
Erlotinib—Depression—Carmustine—malignant glioma	0.000811	0.00616	CcSEcCtD
Erlotinib—MKNK1—central nervous system—malignant glioma	0.000809	0.00951	CbGeAlD
Erlotinib—ABL1—telencephalon—malignant glioma	0.000807	0.00949	CbGeAlD
Erlotinib—Renal failure—Carmustine—malignant glioma	0.000799	0.00607	CcSEcCtD
Erlotinib—Weight decreased—Temozolomide—malignant glioma	0.000797	0.00605	CcSEcCtD
Erlotinib—Neuropathy peripheral—Carmustine—malignant glioma	0.000797	0.00605	CcSEcCtD
Erlotinib—Stomatitis—Carmustine—malignant glioma	0.000793	0.00602	CcSEcCtD
Erlotinib—MKNK1—cerebellum—malignant glioma	0.000791	0.00929	CbGeAlD
Erlotinib—Pneumonia—Temozolomide—malignant glioma	0.00079	0.006	CcSEcCtD
Erlotinib—Infestation NOS—Temozolomide—malignant glioma	0.000786	0.00597	CcSEcCtD
Erlotinib—Infestation—Temozolomide—malignant glioma	0.000786	0.00597	CcSEcCtD
Erlotinib—Depression—Temozolomide—malignant glioma	0.000784	0.00595	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000779	0.00592	CcSEcCtD
Erlotinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.00077	0.00585	CcSEcCtD
Erlotinib—Stomatitis—Temozolomide—malignant glioma	0.000766	0.00582	CcSEcCtD
Erlotinib—ABL2—brain—malignant glioma	0.000755	0.00888	CbGeAlD
Erlotinib—MAP2K5—midbrain—malignant glioma	0.000751	0.00884	CbGeAlD
Erlotinib—SLK—cerebellum—malignant glioma	0.000749	0.0088	CbGeAlD
Erlotinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000743	0.00564	CcSEcCtD
Erlotinib—EGFR—brain—malignant glioma	0.000737	0.00867	CbGeAlD
Erlotinib—Haemoglobin—Carmustine—malignant glioma	0.000734	0.00557	CcSEcCtD
Erlotinib—MAP2K5—spinal cord—malignant glioma	0.000733	0.00862	CbGeAlD
Erlotinib—Haemorrhage—Carmustine—malignant glioma	0.00073	0.00554	CcSEcCtD
Erlotinib—Connective tissue disorder—Carmustine—malignant glioma	0.000717	0.00545	CcSEcCtD
Erlotinib—PIP4K2C—brain—malignant glioma	0.000714	0.0084	CbGeAlD
Erlotinib—Haemoglobin—Temozolomide—malignant glioma	0.000709	0.00538	CcSEcCtD
Erlotinib—Hepatitis—Temozolomide—malignant glioma	0.000705	0.00536	CcSEcCtD
Erlotinib—Haemorrhage—Temozolomide—malignant glioma	0.000705	0.00536	CcSEcCtD
Erlotinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000697	0.00529	CcSEcCtD
Erlotinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000693	0.00526	CcSEcCtD
Erlotinib—Urethral disorder—Temozolomide—malignant glioma	0.000691	0.00525	CcSEcCtD
Erlotinib—CYP1B1—telencephalon—malignant glioma	0.000684	0.00804	CbGeAlD
Erlotinib—ULK3—brain—malignant glioma	0.000682	0.00802	CbGeAlD
Erlotinib—Eye disorder—Carmustine—malignant glioma	0.000682	0.00518	CcSEcCtD
Erlotinib—Erythema multiforme—Temozolomide—malignant glioma	0.000667	0.00506	CcSEcCtD
Erlotinib—STK10—central nervous system—malignant glioma	0.000666	0.00783	CbGeAlD
Erlotinib—Eye disorder—Temozolomide—malignant glioma	0.000659	0.00501	CcSEcCtD
Erlotinib—Arrhythmia—Carmustine—malignant glioma	0.000652	0.00495	CcSEcCtD
Erlotinib—STK10—cerebellum—malignant glioma	0.000651	0.00765	CbGeAlD
Erlotinib—Alopecia—Carmustine—malignant glioma	0.000645	0.0049	CcSEcCtD
Erlotinib—MKNK1—brain—malignant glioma	0.000642	0.00755	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—malignant glioma	0.00064	0.00752	CbGeAlD
Erlotinib—Mental disorder—Carmustine—malignant glioma	0.00064	0.00486	CcSEcCtD
Erlotinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000636	0.00483	CcSEcCtD
Erlotinib—Malnutrition—Carmustine—malignant glioma	0.000635	0.00483	CcSEcCtD
Erlotinib—Erythema—Carmustine—malignant glioma	0.000635	0.00483	CcSEcCtD
Erlotinib—ABL1—medulla oblongata—malignant glioma	0.000634	0.00746	CbGeAlD
Erlotinib—Chills—Temozolomide—malignant glioma	0.000633	0.00481	CcSEcCtD
Erlotinib—Alopecia—Temozolomide—malignant glioma	0.000623	0.00473	CcSEcCtD
Erlotinib—Mental disorder—Temozolomide—malignant glioma	0.000618	0.00469	CcSEcCtD
Erlotinib—Back pain—Carmustine—malignant glioma	0.000615	0.00467	CcSEcCtD
Erlotinib—Erythema—Temozolomide—malignant glioma	0.000614	0.00466	CcSEcCtD
Erlotinib—Malnutrition—Temozolomide—malignant glioma	0.000614	0.00466	CcSEcCtD
Erlotinib—SLK—brain—malignant glioma	0.000608	0.00715	CbGeAlD
Erlotinib—ORM1—spinal cord—malignant glioma	0.000595	0.007	CbGeAlD
Erlotinib—MAP2K5—central nervous system—malignant glioma	0.000595	0.00699	CbGeAlD
Erlotinib—Back pain—Temozolomide—malignant glioma	0.000594	0.00451	CcSEcCtD
Erlotinib—MAP2K5—cerebellum—malignant glioma	0.000581	0.00684	CbGeAlD
Erlotinib—ABL1—midbrain—malignant glioma	0.00058	0.00682	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—malignant glioma	0.000571	0.00671	CbGeAlD
Erlotinib—ABL1—spinal cord—malignant glioma	0.000566	0.00665	CbGeAlD
Erlotinib—Chest pain—Carmustine—malignant glioma	0.000541	0.00411	CcSEcCtD
Erlotinib—Myalgia—Carmustine—malignant glioma	0.000541	0.00411	CcSEcCtD
Erlotinib—Anxiety—Carmustine—malignant glioma	0.000539	0.00409	CcSEcCtD
Erlotinib—Cough—Temozolomide—malignant glioma	0.000536	0.00407	CcSEcCtD
Erlotinib—STK10—brain—malignant glioma	0.000529	0.00622	CbGeAlD
Erlotinib—Arthralgia—Temozolomide—malignant glioma	0.000523	0.00397	CcSEcCtD
Erlotinib—Myalgia—Temozolomide—malignant glioma	0.000523	0.00397	CcSEcCtD
Erlotinib—Anxiety—Temozolomide—malignant glioma	0.000521	0.00396	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000519	0.00394	CcSEcCtD
Erlotinib—Oedema—Carmustine—malignant glioma	0.000519	0.00394	CcSEcCtD
Erlotinib—ABCB1—blood vessel—malignant glioma	0.000517	0.00608	CbGeAlD
Erlotinib—Infection—Carmustine—malignant glioma	0.000515	0.00391	CcSEcCtD
Erlotinib—ABCG2—telencephalon—malignant glioma	0.000509	0.00599	CbGeAlD
Erlotinib—Thrombocytopenia—Carmustine—malignant glioma	0.000508	0.00386	CcSEcCtD
Erlotinib—Oedema—Temozolomide—malignant glioma	0.000501	0.00381	CcSEcCtD
Erlotinib—Infection—Temozolomide—malignant glioma	0.000498	0.00378	CcSEcCtD
Erlotinib—Anorexia—Carmustine—malignant glioma	0.000494	0.00375	CcSEcCtD
Erlotinib—Nervous system disorder—Temozolomide—malignant glioma	0.000491	0.00373	CcSEcCtD
Erlotinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000491	0.00373	CcSEcCtD
Erlotinib—Skin disorder—Temozolomide—malignant glioma	0.000487	0.0037	CcSEcCtD
Erlotinib—ORM1—central nervous system—malignant glioma	0.000483	0.00568	CbGeAlD
Erlotinib—Anorexia—Temozolomide—malignant glioma	0.000478	0.00363	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000472	0.00359	CcSEcCtD
Erlotinib—MAP2K5—brain—malignant glioma	0.000472	0.00555	CbGeAlD
Erlotinib—Insomnia—Carmustine—malignant glioma	0.000469	0.00356	CcSEcCtD
Erlotinib—SLCO2B1—central nervous system—malignant glioma	0.000463	0.00544	CbGeAlD
Erlotinib—Dyspnoea—Carmustine—malignant glioma	0.000462	0.00351	CcSEcCtD
Erlotinib—ABL1—central nervous system—malignant glioma	0.000459	0.00539	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000457	0.00347	CcSEcCtD
Erlotinib—Insomnia—Temozolomide—malignant glioma	0.000453	0.00344	CcSEcCtD
Erlotinib—SLCO2B1—cerebellum—malignant glioma	0.000452	0.00532	CbGeAlD
Erlotinib—Decreased appetite—Carmustine—malignant glioma	0.000451	0.00342	CcSEcCtD
Erlotinib—ABL1—cerebellum—malignant glioma	0.000448	0.00527	CbGeAlD
Erlotinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000448	0.0034	CcSEcCtD
Erlotinib—Dyspnoea—Temozolomide—malignant glioma	0.000447	0.00339	CcSEcCtD
Erlotinib—Pain—Carmustine—malignant glioma	0.000443	0.00337	CcSEcCtD
Erlotinib—Constipation—Carmustine—malignant glioma	0.000443	0.00337	CcSEcCtD
Erlotinib—Dyspepsia—Temozolomide—malignant glioma	0.000441	0.00335	CcSEcCtD
Erlotinib—Decreased appetite—Temozolomide—malignant glioma	0.000436	0.00331	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000433	0.00329	CcSEcCtD
Erlotinib—Fatigue—Temozolomide—malignant glioma	0.000432	0.00328	CcSEcCtD
Erlotinib—Pain—Temozolomide—malignant glioma	0.000429	0.00325	CcSEcCtD
Erlotinib—Constipation—Temozolomide—malignant glioma	0.000429	0.00325	CcSEcCtD
Erlotinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000424	0.00322	CcSEcCtD
Erlotinib—Abdominal pain—Carmustine—malignant glioma	0.00041	0.00311	CcSEcCtD
Erlotinib—Body temperature increased—Carmustine—malignant glioma	0.00041	0.00311	CcSEcCtD
Erlotinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.00041	0.00311	CcSEcCtD
Erlotinib—ABCG2—medulla oblongata—malignant glioma	0.0004	0.0047	CbGeAlD
Erlotinib—Abdominal pain—Temozolomide—malignant glioma	0.000396	0.00301	CcSEcCtD
Erlotinib—Body temperature increased—Temozolomide—malignant glioma	0.000396	0.00301	CcSEcCtD
Erlotinib—CYP2D6—brainstem—malignant glioma	0.000393	0.00462	CbGeAlD
Erlotinib—CYP1B1—central nervous system—malignant glioma	0.000389	0.00457	CbGeAlD
Erlotinib—CYP1B1—cerebellum—malignant glioma	0.00038	0.00447	CbGeAlD
Erlotinib—Asthenia—Carmustine—malignant glioma	0.000372	0.00283	CcSEcCtD
Erlotinib—SLCO2B1—brain—malignant glioma	0.000367	0.00432	CbGeAlD
Erlotinib—ABCG2—midbrain—malignant glioma	0.000366	0.0043	CbGeAlD
Erlotinib—ABL1—brain—malignant glioma	0.000364	0.00428	CbGeAlD
Erlotinib—Asthenia—Temozolomide—malignant glioma	0.00036	0.00273	CcSEcCtD
Erlotinib—ABCG2—spinal cord—malignant glioma	0.000357	0.00419	CbGeAlD
Erlotinib—Diarrhoea—Carmustine—malignant glioma	0.000355	0.00269	CcSEcCtD
Erlotinib—Pruritus—Temozolomide—malignant glioma	0.000355	0.00269	CcSEcCtD
Erlotinib—CYP2D6—telencephalon—malignant glioma	0.000349	0.0041	CbGeAlD
Erlotinib—Dizziness—Carmustine—malignant glioma	0.000343	0.0026	CcSEcCtD
Erlotinib—Diarrhoea—Temozolomide—malignant glioma	0.000343	0.0026	CcSEcCtD
Erlotinib—ALB—brain—malignant glioma	0.000336	0.00395	CbGeAlD
Erlotinib—Dizziness—Temozolomide—malignant glioma	0.000331	0.00252	CcSEcCtD
Erlotinib—Vomiting—Carmustine—malignant glioma	0.00033	0.0025	CcSEcCtD
Erlotinib—Rash—Carmustine—malignant glioma	0.000327	0.00248	CcSEcCtD
Erlotinib—Dermatitis—Carmustine—malignant glioma	0.000327	0.00248	CcSEcCtD
Erlotinib—Headache—Carmustine—malignant glioma	0.000325	0.00247	CcSEcCtD
Erlotinib—Vomiting—Temozolomide—malignant glioma	0.000319	0.00242	CcSEcCtD
Erlotinib—Rash—Temozolomide—malignant glioma	0.000316	0.0024	CcSEcCtD
Erlotinib—Dermatitis—Temozolomide—malignant glioma	0.000316	0.0024	CcSEcCtD
Erlotinib—Headache—Temozolomide—malignant glioma	0.000314	0.00238	CcSEcCtD
Erlotinib—ABCB1—embryo—malignant glioma	0.000309	0.00363	CbGeAlD
Erlotinib—CYP1B1—brain—malignant glioma	0.000308	0.00363	CbGeAlD
Erlotinib—Nausea—Carmustine—malignant glioma	0.000308	0.00234	CcSEcCtD
Erlotinib—Nausea—Temozolomide—malignant glioma	0.000298	0.00226	CcSEcCtD
Erlotinib—ABCG2—cerebellum—malignant glioma	0.000283	0.00333	CbGeAlD
Erlotinib—CYP1A1—central nervous system—malignant glioma	0.000275	0.00323	CbGeAlD
Erlotinib—ABCB1—retina—malignant glioma	0.000273	0.00321	CbGeAlD
Erlotinib—ABCB1—telencephalon—malignant glioma	0.000251	0.00295	CbGeAlD
Erlotinib—CYP2C8—brain—malignant glioma	0.000236	0.00278	CbGeAlD
Erlotinib—ABCG2—brain—malignant glioma	0.00023	0.0027	CbGeAlD
Erlotinib—CYP1A1—brain—malignant glioma	0.000218	0.00256	CbGeAlD
Erlotinib—CYP3A4—central nervous system—malignant glioma	0.000202	0.00237	CbGeAlD
Erlotinib—CYP2D6—central nervous system—malignant glioma	0.000198	0.00233	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—malignant glioma	0.000197	0.00232	CbGeAlD
Erlotinib—CYP2D6—cerebellum—malignant glioma	0.000194	0.00228	CbGeAlD
Erlotinib—ABCB1—midbrain—malignant glioma	0.00018	0.00212	CbGeAlD
Erlotinib—ABCB1—spinal cord—malignant glioma	0.000176	0.00207	CbGeAlD
Erlotinib—CYP2D6—brain—malignant glioma	0.000157	0.00185	CbGeAlD
Erlotinib—ABCB1—central nervous system—malignant glioma	0.000143	0.00168	CbGeAlD
Erlotinib—ABCB1—cerebellum—malignant glioma	0.000139	0.00164	CbGeAlD
Erlotinib—ABCB1—brain—malignant glioma	0.000113	0.00133	CbGeAlD
Erlotinib—EGFR—Immune System—IFNG—malignant glioma	6.05e-06	2.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MDM2—malignant glioma	6.01e-06	2.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RAF1—malignant glioma	5.99e-06	2.75e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTT1—malignant glioma	5.94e-06	2.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF2—malignant glioma	5.93e-06	2.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—malignant glioma	5.93e-06	2.72e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—malignant glioma	5.92e-06	2.71e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS1—malignant glioma	5.9e-06	2.71e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—malignant glioma	5.9e-06	2.71e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH2—malignant glioma	5.89e-06	2.7e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.88e-06	2.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—malignant glioma	5.88e-06	2.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—malignant glioma	5.88e-06	2.7e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	5.86e-06	2.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—malignant glioma	5.86e-06	2.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—malignant glioma	5.85e-06	2.69e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.85e-06	2.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CB—malignant glioma	5.85e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—malignant glioma	5.85e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.83e-06	2.68e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.8e-06	2.66e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—malignant glioma	5.79e-06	2.66e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—malignant glioma	5.74e-06	2.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PDGFB—malignant glioma	5.72e-06	2.62e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—malignant glioma	5.71e-06	2.62e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CD—malignant glioma	5.71e-06	2.62e-05	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	5.7e-06	2.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR1—malignant glioma	5.69e-06	2.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—malignant glioma	5.66e-06	2.6e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAT—malignant glioma	5.63e-06	2.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HIF1A—malignant glioma	5.6e-06	2.57e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS1—malignant glioma	5.56e-06	2.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MDM2—malignant glioma	5.55e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.55e-06	2.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2B6—malignant glioma	5.53e-06	2.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—RAF1—malignant glioma	5.53e-06	2.54e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CG—malignant glioma	5.51e-06	2.53e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—malignant glioma	5.5e-06	2.52e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BCHE—malignant glioma	5.49e-06	2.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—malignant glioma	5.47e-06	2.51e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—malignant glioma	5.47e-06	2.51e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—malignant glioma	5.45e-06	2.5e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—malignant glioma	5.42e-06	2.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CAV1—malignant glioma	5.42e-06	2.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CB—malignant glioma	5.4e-06	2.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—malignant glioma	5.39e-06	2.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—malignant glioma	5.37e-06	2.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—malignant glioma	5.36e-06	2.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—malignant glioma	5.35e-06	2.46e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	5.34e-06	2.45e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CD—malignant glioma	5.33e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAT—malignant glioma	5.32e-06	2.44e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—malignant glioma	5.32e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NCOR1—malignant glioma	5.32e-06	2.44e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—malignant glioma	5.29e-06	2.43e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—malignant glioma	5.27e-06	2.42e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BCHE—malignant glioma	5.17e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—F2—malignant glioma	5.16e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FN1—malignant glioma	5.16e-06	2.37e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	5.15e-06	2.37e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—malignant glioma	5.11e-06	2.34e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—malignant glioma	5.1e-06	2.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BAD—malignant glioma	5.1e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.08e-06	2.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH1—malignant glioma	5.06e-06	2.32e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—malignant glioma	5.06e-06	2.32e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.06e-06	2.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—malignant glioma	5.06e-06	2.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—malignant glioma	5.05e-06	2.32e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—malignant glioma	5.03e-06	2.31e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NCOR1—malignant glioma	5.02e-06	2.31e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—malignant glioma	5.02e-06	2.3e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—malignant glioma	5.01e-06	2.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—malignant glioma	5e-06	2.29e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	4.99e-06	2.29e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—malignant glioma	4.98e-06	2.29e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CB—malignant glioma	4.98e-06	2.28e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—malignant glioma	4.95e-06	2.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CD80—malignant glioma	4.95e-06	2.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—malignant glioma	4.94e-06	2.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—malignant glioma	4.94e-06	2.26e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—malignant glioma	4.93e-06	2.26e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SPHK1—malignant glioma	4.9e-06	2.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EGF—malignant glioma	4.88e-06	2.24e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAT—malignant glioma	4.88e-06	2.24e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAT—malignant glioma	4.85e-06	2.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTPN11—malignant glioma	4.85e-06	2.23e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—malignant glioma	4.84e-06	2.22e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—malignant glioma	4.81e-06	2.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—malignant glioma	4.8e-06	2.2e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2C18—malignant glioma	4.8e-06	2.2e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS1—malignant glioma	4.71e-06	2.16e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	4.7e-06	2.15e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—malignant glioma	4.68e-06	2.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—malignant glioma	4.67e-06	2.14e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—malignant glioma	4.64e-06	2.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—malignant glioma	4.64e-06	2.13e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NCOR1—malignant glioma	4.61e-06	2.11e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—malignant glioma	4.6e-06	2.11e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NCOR1—malignant glioma	4.58e-06	2.1e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—malignant glioma	4.54e-06	2.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—malignant glioma	4.52e-06	2.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT2—malignant glioma	4.52e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BCHE—malignant glioma	4.38e-06	2.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—malignant glioma	4.37e-06	2e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—malignant glioma	4.34e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAV1—malignant glioma	4.33e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—malignant glioma	4.33e-06	1.99e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—malignant glioma	4.31e-06	1.98e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—malignant glioma	4.3e-06	1.97e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—malignant glioma	4.3e-06	1.97e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—malignant glioma	4.26e-06	1.96e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAT—malignant glioma	4.25e-06	1.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—malignant glioma	4.25e-06	1.95e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—malignant glioma	4.22e-06	1.94e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—malignant glioma	4.18e-06	1.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—malignant glioma	4.17e-06	1.92e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—malignant glioma	4.17e-06	1.91e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—malignant glioma	4.16e-06	1.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—malignant glioma	4.15e-06	1.91e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—malignant glioma	4.11e-06	1.89e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—malignant glioma	4.1e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.09e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.06e-06	1.86e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NCOR1—malignant glioma	4.01e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—malignant glioma	4.01e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAT—malignant glioma	4e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—malignant glioma	3.95e-06	1.81e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—malignant glioma	3.92e-06	1.8e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.91e-06	1.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—malignant glioma	3.9e-06	1.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—malignant glioma	3.89e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—malignant glioma	3.88e-06	1.78e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—malignant glioma	3.88e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—malignant glioma	3.88e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RAF1—malignant glioma	3.87e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—malignant glioma	3.83e-06	1.76e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—malignant glioma	3.81e-06	1.75e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—malignant glioma	3.79e-06	1.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—malignant glioma	3.78e-06	1.74e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NCOR1—malignant glioma	3.78e-06	1.73e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—malignant glioma	3.75e-06	1.72e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—malignant glioma	3.73e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—malignant glioma	3.73e-06	1.71e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—malignant glioma	3.65e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS1—malignant glioma	3.64e-06	1.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—malignant glioma	3.63e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—malignant glioma	3.6e-06	1.65e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.59e-06	1.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—malignant glioma	3.58e-06	1.64e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.57e-06	1.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—malignant glioma	3.57e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	3.54e-06	1.62e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—malignant glioma	3.51e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—malignant glioma	3.49e-06	1.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—malignant glioma	3.48e-06	1.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—malignant glioma	3.47e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—malignant glioma	3.47e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—malignant glioma	3.42e-06	1.57e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—malignant glioma	3.41e-06	1.56e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—malignant glioma	3.4e-06	1.56e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAT—malignant glioma	3.39e-06	1.56e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—malignant glioma	3.38e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.34e-06	1.53e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—malignant glioma	3.3e-06	1.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—malignant glioma	3.29e-06	1.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—malignant glioma	3.29e-06	1.51e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—malignant glioma	3.28e-06	1.51e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—malignant glioma	3.28e-06	1.5e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—malignant glioma	3.27e-06	1.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—malignant glioma	3.27e-06	1.5e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOR1—malignant glioma	3.2e-06	1.47e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—malignant glioma	3.2e-06	1.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—malignant glioma	3.19e-06	1.46e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—malignant glioma	3.08e-06	1.41e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—malignant glioma	3.03e-06	1.39e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—malignant glioma	3.03e-06	1.39e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—malignant glioma	3.01e-06	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—malignant glioma	3e-06	1.38e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—malignant glioma	2.99e-06	1.37e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—malignant glioma	2.98e-06	1.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—malignant glioma	2.95e-06	1.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—malignant glioma	2.92e-06	1.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—malignant glioma	2.91e-06	1.34e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—malignant glioma	2.88e-06	1.32e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—malignant glioma	2.86e-06	1.31e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—malignant glioma	2.83e-06	1.3e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—malignant glioma	2.83e-06	1.3e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—malignant glioma	2.81e-06	1.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—malignant glioma	2.72e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—malignant glioma	2.71e-06	1.24e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—malignant glioma	2.69e-06	1.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—malignant glioma	2.69e-06	1.23e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—malignant glioma	2.62e-06	1.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—malignant glioma	2.62e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAT—malignant glioma	2.62e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—malignant glioma	2.61e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—malignant glioma	2.61e-06	1.2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—malignant glioma	2.61e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—malignant glioma	2.6e-06	1.19e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—malignant glioma	2.58e-06	1.18e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—malignant glioma	2.57e-06	1.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—malignant glioma	2.51e-06	1.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.49e-06	1.14e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—malignant glioma	2.48e-06	1.14e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOR1—malignant glioma	2.47e-06	1.13e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—malignant glioma	2.47e-06	1.13e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.47e-06	1.13e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—malignant glioma	2.38e-06	1.09e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—malignant glioma	2.31e-06	1.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—malignant glioma	2.31e-06	1.06e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—malignant glioma	2.3e-06	1.05e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—malignant glioma	2.28e-06	1.05e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—malignant glioma	2.26e-06	1.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—malignant glioma	2.26e-06	1.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—malignant glioma	2.25e-06	1.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—malignant glioma	2.23e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.15e-06	9.87e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—malignant glioma	2.13e-06	9.78e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—malignant glioma	2.1e-06	9.65e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.09e-06	9.59e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—malignant glioma	2.02e-06	9.25e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—malignant glioma	1.97e-06	9.05e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—malignant glioma	1.88e-06	8.64e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—malignant glioma	1.86e-06	8.53e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—malignant glioma	1.84e-06	8.46e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.84e-06	8.42e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—malignant glioma	1.82e-06	8.36e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—malignant glioma	1.81e-06	8.29e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—malignant glioma	1.77e-06	8.13e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—malignant glioma	1.74e-06	7.99e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.61e-06	7.4e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—malignant glioma	1.6e-06	7.33e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—malignant glioma	1.59e-06	7.29e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—malignant glioma	1.57e-06	7.23e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—malignant glioma	1.51e-06	6.91e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—malignant glioma	1.42e-06	6.53e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.41e-06	6.45e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—malignant glioma	1.39e-06	6.39e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—malignant glioma	1.39e-06	6.39e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.31e-06	6.02e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—malignant glioma	1.31e-06	5.99e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—malignant glioma	1.3e-06	5.95e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—malignant glioma	1.22e-06	5.58e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—malignant glioma	1.14e-06	5.22e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.11e-06	5.1e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—malignant glioma	1.07e-06	4.92e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—malignant glioma	9.08e-07	4.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	8.57e-07	3.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—malignant glioma	7e-07	3.21e-06	CbGpPWpGaD
